Phase 1b/2 Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of CFI-400945 as a Single Agent or in Combination With Azacitidine in Patients With AML, MDS or CMML
Latest Information Update: 09 Feb 2024
At a glance
- Drugs Azacitidine (Primary) ; Decitabine (Primary) ; Ocifisertib (Primary)
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors Treadwell Therapeutics
- 02 Feb 2024 Planned End Date changed from 1 Jan 2024 to 1 Jan 2026.
- 02 Feb 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Jan 2026.
- 15 Dec 2023 According to a Treadwell Therapeutics media release, company looking forward into dose expansion studies in monotherapy and in combination in 2024.